Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
36 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsEuropean Commission approves Roche´s MabThera (rituximab) for a rare autoimmune disease
(WorldNews Switzerland)

 
 

15 march 2019 08:01:39

 
European Commission approves Roche´s MabThera (rituximab) for a rare autoimmune disease
(WorldNews Switzerland)
 


Basel, 15 March 2019 European Commission approves Roche`s MabThera (rituximab) for a rare autoimmune disease MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease in more than 60 years PV is a rare and potentially life-threatening blistering condition which can cause severe pain and disfigurement MabThera is now approved in Europe to treat four autoimmune diseases Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved MabTheraŽ (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris...


 
6 viewsCategory: General > Europe > Switzerland
 
UBS publishes Annual Report 2018
(WorldNews Switzerland)
Molecular Partners Publishes Audited Financial Results for 2018 and Annual Report 2018
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten